Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bioscience Fiscal Q3 Revenues Rise 7 Percent as Acquisition Looms

NEW YORK – Meridian Bioscience reported on Friday morning a 7 percent year-over-year increase in its fiscal third quarter revenues, one month after announcing it will be acquired by a newly formed affiliate of SD Biosensor and SJL Partners.

The Cincinnati-based life science and diagnostics firm recorded total revenues of $67.8 million compared to $63.5 million a year ago. The revenues were in line with Meridian's preliminary results released in July.

Its life science revenues for the quarter were down 21 percent at $25.4 million compared to $32.3 million a year ago. Within the segment, Meridian Bioscience's fiscal Q3 molecular reagent product revenues fell 62 percent year over year to $7.7 million from $20.4 million, while immunological reagent revenues rose 48 percent year over year to $17.6 million from $11.9 million.

The shift from molecular to immunological regents was driven by lower overall demand in fiscal 2022 for molecular tests related to COVID-19, Meridian said in a statement.

Meanwhile, Meridian Bioscience's diagnostics revenues were up 36 percent year over year to $42.4 million from $31.2 million.

Within diagnostics, revenues for molecular assays grew 11 percent to $4.9 million from $4.4 million, while revenues from non-molecular assays grew 40 percent to $37.5 million from $26.8 million. For non-molecular assays, the increase was driven by demand for BreathTek tests and a rise in LeadCare product sales after a product recall affected fiscal Q3 2021 sales. Within the company's disease categories, gastrointestinal assays contributed most to the diagnostics revenues, rising to $22.7 million from $17.8 million in 2021.

Meridian Bioscience's fiscal Q3 net loss was $7.3 million, or $.16 per share, compared to $11.7 million, or $.26 per share a year ago. On an adjusted basis, EPS was $.16.

The firm noted that it paid $11.8 million in litigation and select legal costs during the quarter, compared to $438,000 in 2021. The increase was due to the accrual of $10 million to possibly settle its legal matter with the US Department of Justice related to its subsidiary Magellan's LeadCare product line, as well as $1.8 million in attorneys' fees related to the dispute, the company disclosed in its form 10-Q filed with the US Securities and Exchange Commission.

The firm finished the quarter with $83.5 million in cash and cash equivalents.

In morning trading on the Nasdaq, Meridian's shares were up 2 percent at $32.24.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.